Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting | Zendy

Noam Barda | Zendy; Noa Dagan | Zendy; Yatir BenShlomo | Zendy; Eldad Kepten | Zendy; Jacob Waxman | Zendy; Reut Ohana | Zendy; Miguel A. Hernán | Zendy; Marc Lipsitch | Zendy; Isaac S. Kohane | Zendy; Doron Netzer | Zendy; Ben Y. Reis | Zendy; Ran D. Balicer | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting

Author(s) -

Noam Barda,

Noa Dagan,

Yatir BenShlomo,

Eldad Kepten,

Jacob Waxman,

Reut Ohana,

Miguel A. Hernán,

Marc Lipsitch,

Isaac S. Kohane,

Doron Netzer,

Ben Y. Reis,

Ran D. Balicer

Publication year - 2021

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa2110475

Subject(s) - medicine , vaccination , adverse effect , context (archaeology) , confidence interval , adverse event reporting system , population , absolute risk reduction , immunology , environmental health , paleontology , biology

Preapproval trials showed that messenger RNA (mRNA)-based vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) had a good safety profile, yet these trials were subject to size and patient-mix limitations. An evaluation of the safety of the BNT162b2 mRNA vaccine with respect to a broad range of potential adverse events is needed.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research